ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy And Safety Of Azithromycin SR Compared With Minocycline In Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00392223
Recruitment Status : Terminated (See Detailed Description)
First Posted : October 25, 2006
Results First Posted : August 3, 2009
Last Update Posted : January 12, 2010
Sponsor:
Information provided by:
Pfizer

Brief Summary:
The primary objective is to evaluate the clinical efficacy of azithromycin microspheres treatment in outpatients with moderate to severe inflammatory acne compared with first line treatment minocycline after 8 weeks of therapy

Condition or disease Intervention/treatment Phase
Acne Vulgaris Drug: Azithromycin microspheres Drug: minocycline-placebo capsules Drug: Azithromycin microspheres-placebo Drug: Minocycline capsules, Phase 3

Detailed Description:
The study prematurely discontinued on the February 1, 2008 due to slow enrollment.It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double Blind-Double Dummy Study, To Evaluate Efficacy And Safety Of Treatment With Azithromycin, Microspheres, Oral Powder For Suspension, 2 G, In One Administration A Week, For 8 Weeks, Compared With Treatment With Minocycline Capsules, 100 Mg Die For 8 Weeks, In Outpatients With Moderate To Severe Inflammatory Acne.
Study Start Date : October 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: Treatment Group A Drug: Azithromycin microspheres
Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo

Drug: minocycline-placebo capsules
minocycline-placebo capsules daily for 8 weeks plus minocycline placebo

Experimental: Treatment Group B Drug: Azithromycin microspheres-placebo
Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.

Drug: Minocycline capsules,
Capsules, PO, 100 mg daily for 8 weeks.




Primary Outcome Measures :
  1. Change From Baseline to End of Treatment in Global Acne Grading System (GAGS) Score [ Time Frame: Baseline, Week 8 End of Treatment (EOT) ]
  2. Change From Baseline to End of Treatment (EOT) in Global Acne Grading System (GAGS) Score - Per Protocol Population [ Time Frame: Baseline, Week 8 EOT ]

Secondary Outcome Measures :
  1. Change From Baseline in Global Acne Grading System (GAGS) Score [ Time Frame: Baseline, Week 4, Week 8 End of Treatment (EOT), 8 weeks after EOT ]
  2. Improvement of Global Acne Grading System (GAGS) Score [ Time Frame: Week 4, Week 8 End of Treatment (EOT), 8 weeks after EOT ]
  3. Change From Baseline in Acne Graded by Leeds Technique [ Time Frame: Baseline, Week 4, Week 8 End of Treatment (EOT), 8 weeks after EOT ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • male and female, > 16 years of age, with diagnosis of acne papulo-pustular, moderate (19-30 GAGS score) to severe (31-33 GAGS score)

Exclusion Criteria:

  • pregnancy, gastrointestinal and endocrinological disease, specific systemic disease, hormonal contraceptives, isotretinoin, topic drugs for acne (except detergent allowed)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00392223


Locations
Italy
Pfizer Investigational Site
Germona Del Friuli, Udine, Italy, 33013
Pfizer Investigational Site
Bologna, Italy, 40121
Pfizer Investigational Site
Catania, Italy, 95124
Pfizer Investigational Site
Catanzaro, Italy, 88100
Pfizer Investigational Site
Ferrara, Italy, 44100
Pfizer Investigational Site
Genova, Italy, 16132
Pfizer Investigational Site
Lucca, Italy, 55100
Pfizer Investigational Site
Messina, Italy, 98100
Pfizer Investigational Site
Milano, Italy, 20100
Pfizer Investigational Site
Napoli, Italy, 80131
Pfizer Investigational Site
Pisa, Italy, 56126
Pfizer Investigational Site
Pordenone, Italy, 33170
Pfizer Investigational Site
Roma, Italy, 00161
Pfizer Investigational Site
Roma, Italy, 00167
Pfizer Investigational Site
Siena, Italy, 53100
Pfizer Investigational Site
Terni, Italy, 05100
Pfizer Investigational Site
Trieste, Italy, 34100
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00392223     History of Changes
Other Study ID Numbers: A0661150
First Posted: October 25, 2006    Key Record Dates
Results First Posted: August 3, 2009
Last Update Posted: January 12, 2010
Last Verified: January 2010

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents